Advertisement
U.S. markets closed
  • S&P Futures

    5,304.25
    -4.00 (-0.08%)
     
  • Dow Futures

    40,140.00
    -36.00 (-0.09%)
     
  • Nasdaq Futures

    18,465.00
    -38.75 (-0.21%)
     
  • Russell 2000 Futures

    2,145.20
    +6.80 (+0.32%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0790
    -0.0003 (-0.03%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • Vix

    13.01
    +0.23 (+1.80%)
     
  • GBP/USD

    1.2621
    -0.0001 (-0.01%)
     
  • USD/JPY

    151.4620
    +0.0900 (+0.06%)
     
  • Bitcoin USD

    70,675.46
    +1,130.42 (+1.63%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,373.52
    +205.45 (+0.51%)
     

Galapagos sees cystic fibrosis clinical trials in 2014

BRUSSELS, Oct 17 (Reuters) - Belgian biotech company Galapagos said on Thursday that it was set to start clinical trials on a possible treatment for cystic fibrosis at the end of 2014.

The company said in a statement that it had developed a series of potentiators following laboratory tests and would be presenting its results at the North America Cystic Fibrosis Conference in Utah on Oct 17-19.

Galapagos said it would nominate a pre-clinical candidate by the end of this year, with first clinical trials set to start at the end of 2014.

Galapagos signed a cooperation deal last month worth up to $405 million with U.S. company AbbVie to develop a new treatment for cystic fibrosis.

Advertisement